SynGenSys introduces Liver.SET synthetic promoter library for liver-specific gene expression for in vivo gene therapies
Validated, tissue-specific library enables customisable and controllable liver-targeted gene expression with high specificity and minimal off-target activity in muscle tissue
Sheffield, UK, 4th February 2026: SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the launch of its Liver.SET™ library of liver-specific synthetic promoters. Developed using SyngenSys’ proprietary informatics and computational design platform, the Liver.SET library comprises a range of compact, patentable synthetic promoters for liver-targeted gene expression for in vivo gene therapies.
Liver.SET overcomes key challenges in cell and gene therapy development by enabling tissue-specific, precise transgene expression with minimal off-target activity in muscle tissue. Validated both in vitro and in vivo for target specificity, the promoters display a marked increase in activity and design flexibility in comparison to natural liver promoters with fixed activity profiles, sizes, and regulatory behaviours. The promoters exhibit low levels of activity in HEK293, avoiding viral vector manufacturing issues linked to therapeutic gene expression during packaging, while the modular architecture of the promoters further supports rapid customisation alongside compact sequence lengths yielding enhanced compatibility with AAV payloads.
Following the launch of SynGenSys’ first tissue-type specific library, NK.SET1,which supports the development of natural killer cell therapies, Liver.SET further demonstrates the ability to design tissue-specific promoters with customisable designs for therapeutic applications. The demonstrated specificity of SynGenSys’ promoters provides a foundation for the development of promoter libraries designed to target and de-target tissues including muscle, retina and CNS. The commercialisation of the validated libraries also demonstrates SynGenSys’ capabilities for tailored promoter design for targeted therapeutics, facilitating the development of safer, more effective cell and gene therapies.
Dr Mike Daniels, ChiefCommercial Officer, SynGenSys, commented: “The launch of Liver.SET™ represents another significant milestone for SynGenSys, demonstrating that our platform can deliver synthetic promoter solutions for real gene therapy development needs. We see this as a key enabler for in vivo gene therapies, and a reliable, validated starting point for deeper collaboration with developers seeking to design novel therapeutics with enhanced precision and safety.”
For further information please click here
About SynGenSys
SynGenSys’ proprietary informatics and computational design platform enables the precise design of synthetic gene promoters to meet strict requirements and address critical bottlenecks in biomanufacturing and cell and gene therapy (CGT). The Company’s team of globally respected scientists has deep expertise in promoter design and development, with a history of delivering high impact projects for some of the world’s leading biopharmaceutical and CGT companies.
SynGenSys is able to rapidly assess the transcriptional landscape of any target tissue, identifying features contributing to off-target expression, while tuning expression requirements. SynGenSys offers a range of off-the-shelf or custom-developed promoter systems to both de-risk and enhance biopharmaceutical production efficiency, quality, and turnaround time — including for production of multi-component and difficult-to express proteins. For cell and gene therapies, SynGenSys provides transcriptional analysis and bespoke promoter design services that enable precise, tunable control of transgene expression. By designing minimal-sized promoters for optimised payload capacity, SynGenSys is supporting the development and delivery of next-generation medicines.
SynGenSys was founded in 2021as a spin-out from the University of Sheffield based on research carried out by founders Professor David James and Dr Adam Brown.
References:
1. https://www.syngensys.com/resources/nk
